Efficacy of Everolimus as Inhibitor of Fibrosis Progression in Liver Transplant Patients With Recurrence of Hepatitis C Viral Infection

Mise à jour : Il y a 4 ans
Référence : NCT00582738

Femme et Homme

  • | Pays :
  • Argentina
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

This study will assess the efficacy of everolimus as an inhibitor of fibrosis progression in liver transplant patients who have a recurrence of hepatitis C viral infection in the transplant


Critère d'inclusion

  • Recurrent Hepatitis C

Liens